KCNQ1OT1 contributes to sorafenib resistance and programmed death-ligand-1-mediated immune escape via sponging miR-506 in hepatocellular carcinoma cells

被引:43
作者
Zhang, Junli [1 ]
Zhao, Xiaohui [2 ]
Ma, Xiaojuan [1 ]
Yuan, Zengyan [1 ]
Hu, Miao [1 ]
机构
[1] Xinxiang Med Univ, Sch Med Lab, Sanquan Coll, 688 East Xiangyang Rd, Xinxiang 453003, Henan, Peoples R China
[2] Xinxiang Med Univ, Sch Basic Med Sci, Sanquan Coll, Xinxiang 453003, Henan, Peoples R China
关键词
hepatocellular carcinoma; sorafenib; KCNQ1 overlapping transcript 1; miR-506; programmed death-ligand-1; SYSTEMIC TREATMENT; TUMOR-SUPPRESSOR; LNCRNA; PATHWAY; TARGETS; RNA;
D O I
10.3892/ijmm.2020.4710
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Drug resistance and immune escape of tumor cells severely compromise the treatment efficiency of hepatocellular carcinoma (HCC). Long non-coding RNA KCNQ1 overlapping transcript 1 (lncRNA KCNQ1OT1) has been shown to be involved in drug resistance in several cancers. The aim of the present study was to investigate the role of KCNQ1OT1 in sorafenib resistance and immune escape of HCC cells. Reverse transcription-quantitative PCR analysis, western blotting and immunohistochemistry were performed to detect the expression of KCNQ1OT1, miR-506 and programmed death-ligand-1 (PD-L1). Cell Counting Kit-8 assay, flow cytometry and Transwell assays were used to evaluate IC50 value, cell apoptosis and metastasis. ELISA was performed to detect the secretion of cytokines. Dual-luciferase reporter assay was conducted to verify the targeting relationships between miR-506 and KCNQ1OT1 or PD-L1. KCNQ1OT1 and PD-L1 were found to be upregulated and miR-506 was downregulated in sorafenib-resistant HCC tissues and cells. Furthermore, KCNQ1OT1 knockdown reduced the IC50 value of sorafenib, suppressed cell metastasis and promoted apoptosis in sorafenib-resistant HCC cells. Moreover, KCNQ1OT1 knockdown changed the tumor microenvironment and T-cell apoptosis in a sorafenib-resistant HCC /T-cell co-culture model. In addition, it was demonstrated that KCNQ1OT1 functioned as a competing endogenous RNA of miR-506 and increased PD-L1 expression in sorafenib-resistant HCC cells. miR-506 inhibition abolished the effects of KCNQ1OT1 knockdown on sorafenib sensitivity, tumor growth, the tumor microenvironment and T-cell apoptosis. In conclusion, KCNQ1OT1 knockdown inhibited sorafenib resistance and PD-L1-mediated immune escape by sponging miR-506 in sorafenib-resistant HCC cells.
引用
收藏
页码:1794 / 1804
页数:11
相关论文
共 41 条
[1]   Cytokine profile determined by data-mining analysis set into clusters of non-small-cell lung cancer patients according to prognosis [J].
Barrera, L. ;
Montes-Servin, E. ;
Barrera, A. ;
Ramirez-Tirado, L. A. ;
Salinas-Parra, F. ;
Banales-Mendez, J. L. ;
Sandoval-Rios, M. ;
Arrieta, O. .
ANNALS OF ONCOLOGY, 2015, 26 (02) :428-435
[2]   PD-L1 is highly expressed in Enzalutamide resistant prostate cancer [J].
Bishop, Jennifer L. ;
Sio, Alexander ;
Angeles, Arkhjamil ;
Roberts, Morgan E. ;
Azad, Arun A. ;
Chi, Kim N. ;
Zoubeidi, Amina .
ONCOTARGET, 2015, 6 (01) :234-242
[3]   Management of Hepatocellular Carcinoma: An Update [J].
Bruix, Jordi ;
Sherman, Morris .
HEPATOLOGY, 2011, 53 (03) :1020-1022
[4]   Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression [J].
Chen, Limo ;
Gibbons, Don L. ;
Goswami, Sangeeta ;
Cortez, Maria Angelica ;
Ahn, Young-Ho ;
Byers, Lauren A. ;
Zhang, Xuejun ;
Yi, Xiaohui ;
Dwyer, David ;
Lin, Wei ;
Diao, Lixia ;
Wang, Jing ;
Roybal, Jonathon D. ;
Patel, Mayuri ;
Ungewiss, Christin ;
Peng, David ;
Antonia, Scott ;
Mediavilla-Varela, Melanie ;
Robertson, Gordon ;
Jones, Steve ;
Suraokar, Milind ;
Welsh, James W. ;
Erez, Baruch ;
Wistuba, Ignacio I. ;
Chen, Lieping ;
Peng, Di ;
Wang, Shanshan ;
Ullrich, Stephen E. ;
Heymach, John V. ;
Kurie, Jonathan M. ;
Qin, F. Xiao-Feng .
NATURE COMMUNICATIONS, 2014, 5
[5]   Long non-coding RNAs in anti-cancer drug resistance [J].
Chen, Qin-nan ;
Wei, Chen-chen ;
Wang, Zhao-xia ;
Sun, Ming .
ONCOTARGET, 2017, 8 (01) :1925-1936
[6]   The Enhanced Metastatic Potential of Hepatocellular Carcinoma (HCC) Cells with Sorafenib Resistance [J].
Chow, Ariel Ka-Man ;
Ng, Lui ;
Lam, Colin Siu-Chi ;
Wong, Sunny Kit-Man ;
Wan, Timothy Ming-Hun ;
Cheng, Nathan Shiu-Man ;
Yau, Thomas Chung-Cheung ;
Poon, Ronnie Tung-Ping ;
Pang, Roberta Wen-Chi .
PLOS ONE, 2013, 8 (11)
[7]  
Cidon EU, 2017, WORLD J HEPATOL, V9, P797, DOI 10.4254/wjh.v9.i18.797
[8]   Advanced hepatocellular carcinoma and sorafenib: Diagnosis, indications, clinical and radiological follow-up [J].
Colagrande, Stefano ;
Regini, Francesco ;
Taliani, Gian Giacomo ;
Nardi, Cosimo ;
Inghilesi, Andrea Lorenzo .
WORLD JOURNAL OF HEPATOLOGY, 2015, 7 (08) :1041-1053
[9]   β-Catenin Activation Promotes Immune Escape and Resistance to Anti-PD-1 Therapy in Hepatocellular Carcinoma [J].
de Galarreta, Marina Ruiz ;
Bresnahan, Erin ;
Molina-Sanchez, Pedro ;
Lindblad, Katherine E. ;
Maier, Barbara ;
Sia, Daniela ;
Puigvehi, Marc ;
Miguela, Vernica ;
Casanova-Acebes, Maria ;
Dhainaut, Maxime ;
Villacorta-Martin, Carlos ;
Singhi, Aatur D. ;
Moghe, Akshata ;
von Felden, Johann ;
Grinspan, Lauren Tal ;
Wang, Shuang ;
Kamphorst, Alice O. ;
Monga, Satdarshan P. ;
Brown, Brian D. ;
Villanueva, Augusto ;
Llovet, Josep M. ;
Merad, Miriam ;
Lujambio, Amaia .
CANCER DISCOVERY, 2019, 9 (08) :1124-1141
[10]  
Eccles SA, 2005, BIOTECHNOL ANN REV, V11, P391, DOI 10.1016/S1387-2656(05)11013-8